Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs ... Empower Pharmacy — over their continued production of altered tirzepatide ...

weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide ...

Fulton Financial Corporation ("Fulton") today announced that it will distribute its first quarter 2025 earnings release and accompanying charts on Tuesday, April 15, at approximately 4:30 p.m. Eastern ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

LLY YTD stock price chart ... FDA’s removal of tirzepatide from its shortage list, which forces compounding pharmacies to stop producing knockoff versions. This ensures Lilly retains exclusive market ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.